公开(公告)号：US20190292533A1

公开(公告)日：2019-09-26

申请号：US16290388

申请日：2019-03-01

Applicant: Allogene Therapeutics, Inc.

Inventor： Andrew Ross NAGER ,  Spencer PARK ,  Javier Fernando CHAPARRO RIGGERS ,  Regina Junhui LIN ,  Thomas John VAN BLARCOM

IPC: C12N9/90 ,  C07K14/705 ,  C07K14/71 ,  C07K14/715 ,  C12N5/0783 ,  A61K35/17

Abstract: The present invention provides inducible chimeric cytokine receptors responsive to a ligand, e.g., a small molecule or protein, uses of such receptors for improving the functional activities of genetically modified immune cells, such as T cells, comprising the inducible chimeric cytokine receptors, and compositions comprising such cells.

公开(公告)号：US20190125799A1

公开(公告)日：2019-05-02

申请号：US16175663

申请日：2018-10-30

Applicant: Allogene Therapeutics, Inc. ,  Les Laboratoires Servier

Inventor： Cyril Alkis KONTO ,  Amina ZINAI

IPC: A61K35/17 ,  C07K16/28 ,  C07K14/705 ,  C07K14/725 ,  A61K31/7076 ,  A61K31/664 ,  A61K39/395 ,  A61P35/00 ,  C12N5/0783 ,  A61K38/17

Abstract: The present disclosure concerns dosages for the treatment of human patients susceptible to or diagnosed with a disease, such as cancer. Provided are methods for administering chimeric antigen receptor (CAR)-T cells. Also provided are compositions and articles of manufacture for use in the methods.

公开(公告)号：US12295362B2

公开(公告)日：2025-05-13

申请号：US17592105

申请日：2022-02-03

Applicant: Allogene Therapeutics, Inc.

Inventor： Muneeswara Babu Medi ,  Zhuojin Xu ,  Jung S. Lee ,  Yajin Ni ,  Mark W. Leonard

IPC: A01N1/125 ,  A61K40/11 ,  A61K40/31 ,  A61K40/42 ,  C12N5/0783

Abstract: Provided herein are formulations and drug product processes that can improve cell viability and minimize waste of the manufactured formulated cells for a drug product.

公开(公告)号：US20240228639A1

公开(公告)日：2024-07-11

申请号：US18540202

申请日：2023-12-14

Applicant: Allogene Therapeutics, Inc.

Inventor： Zea MELTON ,  Siler PANOWSKI ,  Surabhi SRIVATSA SRINIVASAN ,  Thomas John VAN BLARCOM

IPC: C07K16/28 ,  A61K49/00 ,  C07K14/725 ,  G01N33/569

CPC classification number: C07K16/2875 ,  A61K49/0058 ,  C07K14/7051 ,  G01N33/56972 ,  C07K2317/622

Abstract: Provided herein are anti-idiotype antibodies that specifically recognize anti-CD70 antibody moieties, in particular, anti-CD70 antibody moieties present in recombinant receptors, including chimeric antigen receptors (CARs). The disclosure further relates to uses of anti-idiotype antibodies for specifically identifying and/or selecting cells expressing such recombinant receptors, such as anti-CD70 CAR T cells. The disclosure further relates to uses of anti-idiotype antibodies for specifically activating such cells.

公开(公告)号：US20240228636A1

公开(公告)日：2024-07-11

申请号：US18481797

申请日：2023-10-05

Applicant: Cellectis ,  Allogene Therapeutics, Inc.

Inventor： Barbara Johnson SASU ,  Arvind RAJPAL ,  Philippe DUCHATEAU ,  Alexandre JUILLERAT ,  Julien VALTON

IPC: C07K16/28 ,  A61K35/17 ,  A61K39/00 ,  A61K39/395 ,  C07K14/705 ,  C07K14/725 ,  C07K14/735 ,  C07K16/30 ,  C12N5/00 ,  C12N5/0783 ,  G01N15/01 ,  G01N15/10 ,  G01N15/1031 ,  G01N15/14 ,  G01N15/149

CPC classification number: C07K16/2866 ,  A61K35/17 ,  A61K39/0011 ,  A61K39/001176 ,  A61K39/39558 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/70535 ,  C07K14/70578 ,  C07K16/2803 ,  C07K16/2887 ,  C07K16/3061 ,  C12N5/0093 ,  C12N5/0636 ,  C12N5/0638 ,  G01N15/1031 ,  G01N15/14 ,  A61K2039/505 ,  A61K2039/5156 ,  A61K2039/5158 ,  A61K2039/6056 ,  A61K2039/64 ,  C07K2317/24 ,  C07K2317/53 ,  C07K2317/56 ,  C07K2317/622 ,  C07K2319/00 ,  C07K2319/02 ,  C07K2319/03 ,  C12N2510/00 ,  G01N2015/016 ,  G01N2015/1006 ,  G01N2015/1028 ,  G01N15/149

Abstract: A polypeptide encoding a chimeric antigen receptor (CAR) comprising at least one extracellular binding domain that comprises a scFv formed by at least a VH chain and a VL chain specific to an antigen, wherein said extracellular binding domain comprises at least one mAb-specific epitope.

公开(公告)号：US11896617B2

公开(公告)日：2024-02-13

申请号：US16857573

申请日：2020-04-24

Applicant: ALLOGENE THERAPEUTICS, INC.

Inventor： Thomas Charles Pertel ,  Barbra Johnson Sasu ,  Mark W. Leonard

IPC: C12N15/62 ,  A61K35/17 ,  A61P35/00 ,  C07K14/705 ,  C07K16/28 ,  C12N5/0783 ,  A61K39/00

CPC classification number: A61K35/17 ,  A61P35/00 ,  C07K14/70517 ,  C07K14/70596 ,  C07K16/2803 ,  C12N5/0636 ,  A61K2039/505 ,  C07K2317/76 ,  C07K2319/33 ,  C12N2510/00 ,  C12N2740/15043

Abstract: Provided herein are polynucleotides encoding chimeric antigen receptors (CARs) comprising a CD19 antigen binding domain that specifically binds to CD19 and is resistant to rituximab binding; and immune cells comprising these CD19-specific CARs, e.g., CAR-T cells. Also provided are methods of making and using these CD19-specific CARs, and immune cells comprising these CD19-specific CARs.

公开(公告)号：US20240041930A1

公开(公告)日：2024-02-08

申请号：US18484244

申请日：2023-10-10

Applicant: Allogene Therapeutics, Inc. ,  Les Laboratoires Servier

Inventor： Cyril Alkis KONTO ,  Amina ZINAI

IPC: A61K35/17 ,  C07K14/705 ,  C07K14/725 ,  A61K31/7076 ,  A61K31/664 ,  A61K39/395 ,  A61P35/00 ,  C12N5/0783 ,  A61K38/17 ,  C07K16/28 ,  C07K16/30

CPC classification number: A61K35/17 ,  C07K14/70578 ,  C07K14/7051 ,  A61K31/7076 ,  A61K31/664 ,  A61K39/3955 ,  A61P35/00 ,  C12N5/0636 ,  A61K38/1774 ,  A61K38/177 ,  C07K16/2893 ,  C07K14/70517 ,  C07K16/2803 ,  C07K16/3061 ,  C07K2317/565 ,  C07K2319/03 ,  C07K2319/30 ,  A61K2039/545

Abstract: The present disclosure concerns dosages for the treatment of human patients susceptible to or diagnosed with a disease, such as cancer. Provided are methods for administering chimeric antigen receptor (CAR)-T cells. Also provided are compositions and articles of manufacture for use in the methods.

公开(公告)号：US20240016846A1

公开(公告)日：2024-01-18

申请号：US18365014

申请日：2023-08-03

Applicant: Allogene Therapeutics, Inc.

Inventor： Regina Junhui LIN ,  Thomas John VAN BLARCOM ,  Siler PANOWSKI ,  Barbra Johnson SASU

IPC: A61K35/17 ,  C07K14/715 ,  C07K16/28 ,  C07K16/30 ,  C12N15/67

CPC classification number: A61K35/17 ,  C07K14/7155 ,  C07K16/2818 ,  C07K16/30 ,  C12N15/67 ,  A61K38/00

Abstract: Provided herein are PD-1 chimeric cytokine receptors. When present on chimeric antigen receptor (CAR)-bearing immune cells, such receptors allow for increased immune cell activation, proliferation, persistence, and/or potency, when engaged with PD-1 ligands or activation with an anti-PD-1 antibody. Also provided are methods of making and using the chimeric cytokine receptors described herein.

公开(公告)号：US20230346934A1

公开(公告)日：2023-11-02

申请号：US18191955

申请日：2023-03-29

Applicant: Allogene Therapeutics, Inc.

Inventor： Yi ZHANG ,  Silvia K. TACHEVA-GRIGOROVA ,  Barbra Johnson SASU ,  Siler PANOWSKI ,  Regina Junhui LIN ,  Zhe LI

IPC: A61K39/00 ,  C07K14/705 ,  C07K14/71 ,  C07K16/28 ,  C07K16/22 ,  C07K14/725 ,  A61P35/00

CPC classification number: A61K39/4611 ,  C07K14/70521 ,  C07K14/71 ,  C07K16/2827 ,  C07K16/22 ,  C07K14/70507 ,  C07K14/70517 ,  C07K14/7051 ,  A61K39/4631 ,  A61K39/4643 ,  A61P35/00 ,  C07K2319/03 ,  C07K2317/622 ,  C07K2319/02 ,  A61K2239/13 ,  A61K2239/21 ,  A61K2239/22 ,  A61K2239/23 ,  A61K2239/28

Abstract: Provided herein are chimeric switch receptors (CSRs) comprising an ectodomain and/or transmembrane domain derived from an inhibitory receptor (e.g. PD1 or TGFβR2) fused to the transmembrane domain and/or intracellular signaling domain derived from one or more costimulatory proteins (e.g. CD2, CD28, MyD88, DAP10 or ICOS), or variants thereof. The chimeric switch receptors are designed to convert a signal e.g. an inhibitory signal such as an immunosuppressive signal in the form of PD-L1 or TGFβ into a costimulatory signal. Also provided are engineered immune cells engineered to functionally express a chimeric switch receptor and/or a CAR and optionally also a chimeric cytokine receptor (CCR), and populations thereof, methods of making and using the engineered cells, compositions and kits comprising them, and methods of treating e.g. cancer (e.g. solid or hematologic tumors) by administering the cells and the compositions.

公开(公告)号：US11732041B2

公开(公告)日：2023-08-22

申请号：US16851691

申请日：2020-04-17

Applicant: ALLOGENE THERAPEUTICS, INC.

Inventor： Thomas Charles Pertel ,  Barbra Johnson Sasu ,  Tao Sai

IPC: C07K16/28 ,  C07K16/42 ,  A61K35/17

CPC classification number: C07K16/2803 ,  A61K35/17 ,  C07K16/4241 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/92

Abstract: Provided herein are isolated antibodies that specifically bind anti-CD19 chimeric antigen receptors (CARs) derived from a 4G7 scFv. Also provided are methods of making and using these isolated antibodies.